Eris Lifesciences has received an approval from Reserve Bank of India (RBI) to raise foreign investors’ stake in the company to 49%. RBI notified that Foreign Institutional Investors (FIIs)/Foreign Portfolios Investors (FPIs) investment limit under Portfolio Investment Scheme (PIS) in the company has increased from 24% to 49% of its paid up capital. Also, the NRI investment limit under PIS in the company has increased from 10% to 24%.
Eris Lifesciences is engaged in manufacturing, marketing and selling of branded generics within the chronic and acute categories of the Indian Pharmaceutical Market.
